237 related articles for article (PubMed ID: 28695301)
41. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis.
Pietrantonio F; Petrelli F; Coinu A; Di Bartolomeo M; Borgonovo K; Maggi C; Cabiddu M; Iacovelli R; Bossi I; Lonati V; Ghilardi M; de Braud F; Barni S
Eur J Cancer; 2015 Mar; 51(5):587-94. PubMed ID: 25673558
[TBL] [Abstract][Full Text] [Related]
42. Role of first-line anti-epidermal growth factor receptor therapy compared with anti-vascular endothelial growth factor therapy in advanced colorectal cancer: a meta-analysis of randomized clinical trials.
Khattak MA; Martin H; Davidson A; Phillips M
Clin Colorectal Cancer; 2015 Jun; 14(2):81-90. PubMed ID: 25666296
[TBL] [Abstract][Full Text] [Related]
43. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
Maughan TS; Adams RA; Smith CG; Meade AM; Seymour MT; Wilson RH; Idziaszczyk S; Harris R; Fisher D; Kenny SL; Kay E; Mitchell JK; Madi A; Jasani B; James MD; Bridgewater J; Kennedy MJ; Claes B; Lambrechts D; Kaplan R; Cheadle JP;
Lancet; 2011 Jun; 377(9783):2103-14. PubMed ID: 21641636
[TBL] [Abstract][Full Text] [Related]
44. Overall survival of patients with KRAS wild-type tumor treated with FOLFOX/FORFIRI±cetuximab as the first-line treatment for metastatic colorectal cancer: A meta-analysis.
Yang YF; Wang GY; He JL; Wu FP; Zhang YN
Medicine (Baltimore); 2017 Mar; 96(12):e6335. PubMed ID: 28328812
[TBL] [Abstract][Full Text] [Related]
45. The efficacy of panitumumab in refractory metastatic colorectal cancer: A meta-analysis.
Duan KF; Wang H
J BUON; 2019; 24(4):1457-1463. PubMed ID: 31646791
[TBL] [Abstract][Full Text] [Related]
46. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
47. Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome.
García-Foncillas J; Díaz-Rubio E
Clin Transl Oncol; 2010 Aug; 12(8):533-42. PubMed ID: 20709651
[TBL] [Abstract][Full Text] [Related]
48. The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model.
Hoyle M; Crathorne L; Peters J; Jones-Hughes T; Cooper C; Napier M; Tappenden P; Hyde C
Health Technol Assess; 2013 Apr; 17(14):1-237. PubMed ID: 23547747
[TBL] [Abstract][Full Text] [Related]
49. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
Peeters M; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; Tzekova V; Collins S; Oliner KS; Rong A; Gansert J
J Clin Oncol; 2010 Nov; 28(31):4706-13. PubMed ID: 20921462
[TBL] [Abstract][Full Text] [Related]
50. Novel approaches to treatment of advanced colorectal cancer with anti-EGFR monoclonal antibodies.
Zhang W; Gordon M; Lenz HJ
Ann Med; 2006; 38(8):545-51. PubMed ID: 17438669
[TBL] [Abstract][Full Text] [Related]
51. Prognostic importance of tumor location and anti-EGFR therapy in patients with K-RAS wild type metastatic colorectal cancer.
Kucukoner M; Oztekin E; Akdeniz N; Morkuzu S; Yerlikaya H; Urakci Z; Kaplan MA; Isikdogan A
J BUON; 2019; 24(4):1501-1506. PubMed ID: 31646798
[TBL] [Abstract][Full Text] [Related]
52. KRAS status and resistance to epidermal growth factor receptor tyrosine-kinase inhibitor treatment in patients with metastatic colorectal cancer: a meta-analysis.
Li W; Shi Q; Wang W; Liu J; Ren J; Li Q; Hou F
Colorectal Dis; 2014 Nov; 16(11):O370-8. PubMed ID: 25155261
[TBL] [Abstract][Full Text] [Related]
53. Overall and KRAS-specific results of combined cetuximab treatment and chemotherapy for metastatic colorectal cancer: a meta-analysis.
Zhang L; Ma L; Zhou Q
Int J Colorectal Dis; 2011 Aug; 26(8):1025-33. PubMed ID: 21523374
[TBL] [Abstract][Full Text] [Related]
54. Triplet chemotherapy in combination with anti-EGFR agents for the treatment of metastatic colorectal cancer: Current evidence, advances, and future perspectives.
Folprecht G; Martinelli E; Mazard T; Modest DP; Tsuji A; Esser R; Cremolini C; Falcone A
Cancer Treat Rev; 2022 Jan; 102():102301. PubMed ID: 34839118
[TBL] [Abstract][Full Text] [Related]
55. The role of biological therapy in metastatic colorectal cancer after first-line treatment: a meta-analysis of randomised trials.
Segelov E; Chan D; Shapiro J; Price TJ; Karapetis CS; Tebbutt NC; Pavlakis N
Br J Cancer; 2014 Sep; 111(6):1122-31. PubMed ID: 25072258
[TBL] [Abstract][Full Text] [Related]
56. Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Watanabe J; Muro K; Shitara K; Yamazaki K; Shiozawa M; Ohori H; Takashima A; Yokota M; Makiyama A; Akazawa N; Ojima H; Yuasa Y; Miwa K; Yasui H; Oki E; Sato T; Naitoh T; Komatsu Y; Kato T; Hihara M; Soeda J; Misumi T; Yamamoto K; Akagi K; Ochiai A; Uetake H; Tsuchihara K; Yoshino T
JAMA; 2023 Apr; 329(15):1271-1282. PubMed ID: 37071094
[TBL] [Abstract][Full Text] [Related]
57. A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy.
Saridaki Z; Weidhaas JB; Lenz HJ; Laurent-Puig P; Jacobs B; De Schutter J; De Roock W; Salzman DW; Zhang W; Yang D; Pilati C; Bouché O; Piessevaux H; Tejpar S
Clin Cancer Res; 2014 Sep; 20(17):4499-4510. PubMed ID: 25183481
[TBL] [Abstract][Full Text] [Related]
58. Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group.
Moosmann N; von Weikersthal LF; Vehling-Kaiser U; Stauch M; Hass HG; Dietzfelbinger H; Oruzio D; Klein S; Zellmann K; Decker T; Schulze M; Abenhardt W; Puchtler G; Kappauf H; Mittermüller J; Haberl C; Schalhorn A; Jung A; Stintzing S; Heinemann V
J Clin Oncol; 2011 Mar; 29(8):1050-8. PubMed ID: 21300933
[TBL] [Abstract][Full Text] [Related]
59. Meta-analysis of EGFR tyrosine kinase inhibitors compared with chemotherapy as second-line treatment in pretreated advanced non-small cell lung cancer.
Li N; Yang L; Ou W; Zhang L; Zhang SL; Wang SY
PLoS One; 2014; 9(7):e102777. PubMed ID: 25029199
[TBL] [Abstract][Full Text] [Related]
60. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
